BioNanomatrix, a developer of nanoscale platforms for biomedical research, molecular diagnostics and personalized medicine, has received a Phase II grant from the National Human Genome Research Institute of the US National Institutes of Health.
The grant is intended to support further commercial development of BioNanomatrix’s nanoscale whole genome imaging and analysis platform. It follows the company’s completion of work under a similar Phase I grant for initial development of the technology.
The 30-month $2.08m Small Business Investment Research (SBIR) award was made under the BioEngineering Nanotechnology Initiative, an interdisciplinary, multi-institutes consortium with the stated goal of supporting the development of nanotechnologies critical for enabling essential breakthroughs that may have tremendous potential for affecting biomedicine.
Michael Boyce-Jacino, president and CEO of BioNanomatrix, said: BioNanomatrix’s nanoscale technology is intended to allow researchers to directly image and analyze very long, individual intact strands of DNA at the single-molecule level with very high resolution, yielding a great deal of genomic information that is not currently accessible.
We believe our technology has the potential to increase the utility of whole genome imaging and analysis for a wide range of research and diagnostic applications, and we are delighted at National Human Genome Research Institute’s renewed vote of confidence in the potential of our program.